Practice points
_ Sero-negative RA signifies an important disease burden, for which prompt therapeutic
intervention remains to be vulnerable to diagnostic challenges.
_ Currently, there is inadequate evidence to support a modified treatment strategy for the
seronegative RA, even though the value of initial combination DMARD use, and that of B-cell depletion therapy, may be less than in seropositive disease.